by The vaccination of pregnant women against a virus that causes coughing and cold can reduce the risk of “significantly” that their babies are taken to hospital with serious lung infection.
A team of researchers headed by the University of Edinburgh said that the babies delivered to the hospital with the virus were taken to the hospital.
RSV can lead to a severe lung infection called bronchiolitis, which is dangerous for babies and can lead to being included in intensive care.
It is the most important infectious cause of hospital stays for babies in Great Britain and worldwide.
In the study, researchers examined 537 babies in England and Scotland, who were hospitalized in the winter of 2024-25 with serious respiratory diseases.
A total of 391 of the babies were tested positively for RSV.
The team found that mothers of babies who had no RSV had twice as probably received the vaccine before they were born as the mothers of RSV-positive babies (41% in contrast to 19%).
They also found that the vaccine was increased more than two weeks before the birth, increasing the level of protection, whereby the hospital admissions in this group were reduced by 72%, compared to 58% for babies, the mothers of which were vaccinated at any time before childbirth.
The RSV vaccine was introduced throughout the UK in late summer 2024.
The scientists said that the mother led the mother to produce antibodies – proteins that help prevent the virus, cause severe infections – which are then handed over to the fetus and protect protection against heavy RSV in the first six months of their child’s life.
They recommend that women will be vaccinated as soon as possible from 28 weeks of pregnancy to offer the best protection, as this enables more time for the mother to generate and pass on protective antibodies to the baby, but the stitch can be given until birth.
They also said that earlier examinations only result in half of the expected mothers in England and Scotland, which are currently receiving the RSV vaccine, despite the high success in preventing serious illnesses.
The study leader of Dr. Thomas Williams from the Institute for Regeneration and Repair of the University of Edinburgh said: “With the availability of an effective RSV vaccine, which is shown that he significantly reduces the risk of hospitalization in young infants in Great Britain, there is an excellent opportunity for pregnant women in winter, and their infants from the upcoming RSV -Bronchiolitis in this upcoming RSV bronchiolitis this coming winter. ”
Professor Damian Roland from the Leicester Hospitals and University and Pediatric Emergency Medicine said: “Our work shows the value of the vaccination and corresponds to the treatment of the prevention principle of the NHS -10 year -Plan All health systems that optimize the introduction of RSV vaccine vaccine for mothers for mothers.”
The research team was led by the universities of Edinburgh and Leicester and financed by the innovative drug initiative, the respiratory syncytial virus consortium in Europe, the Wellcome Trust and the National Institute for Health and Care Research at Imperial College London.
The study will be published in the magazine The Lancet Child and Young Health.
